Novo Nordisk (NVO), the pharmaceutical company behind Ozempic and Wegovy, gained more than 6%. Earnings reached DKK5.79 per share, above expectations of DKK5.10. FY26 guidance was raised on stronger expected GLP 1 product sales.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
